Examples of using Ranexa in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Do not use Ranexa after the expiry date which is stated on each blister strip of tablets and on the outside of the carton and bottle.
An increase in plasma digoxin concentrations by an average of 1.5-fold has been reported when Ranexa and digoxin are co-administered.
Ranexa may cause dizziness
That prior to Ranexa treatment the patient should tell their doctor if they have any of the following.
a Patient Alert Card(PAC) with the MAH, who must provide this PAC directly to the pharmacy with each Ranexa shipment.
Taking Ranexa with food and drink Ranexa can be taken with
Ranexa 375 mg prolonged-release tablets Ranexa 500 mg prolonged-release tablets Ranexa 750 mg prolonged-release tablets.
The patient carrying this card is treated with Ranexa for symptomatic angina pectoris.
may be increased during co-administration of Ranexa, and lower doses of these medicinal products may be required.
Ranexa may cause side effects such as dizziness(common)
Ranexa 375 mg prolonged-release tablets Ranexa 500 mg prolonged-release tablets Ranexa 750 mg prolonged-release tablets Ranolazine.
with the National Competent Authorities and must provide this PAC directly to the pharmacy with each Ranexa shipment.
What Ranexa looks like and contents of the pack Ranexa prolonged-release tablets are oval shaped tablets.
Ranexa is supplied in cartons containing 30,
If Ranexa is used in patients with a combination of several of these factors,
In the pivotal study, CARISA, Ranexa was added to treatment with atenolol 50 mg once daily, amlodipine 5 mg once daily, or diltiazem 180 mg once daily.
No proarrhythmic effects were observed in 3,162 patients treated with Ranexa based on 7-day Holter monitoring in the MERLIN-TIMI 36 study.
Patients who take Ranexa must be given a‘patient alert card' that summarises the key safety information on the medicine.
Ranexa demonstrated greater efficacy than placebo in prolonging exercise time at trough at 12 weeks for both doses studied when used as an add-on therapy.
Ranexa has been studied in one main study including a total of 823 patients with an average age of 64 years who had had angina pectoris for at least three months.